Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1998 Dec;53(12):1025–1029. doi: 10.1136/thx.53.12.1025

First treatment with inhaled corticosteroids and the prevention of admissions to hospital for asthma

L Blais 1, S Suissa 1, J Boivin 1, P Ernst 1
PMCID: PMC1745145  PMID: 10195073

Abstract

BACKGROUND—Early treatment with inhaled corticosteroids appears to improve clinical symptoms in asthma. Whether a first treatment initiated in the year following the recognition of asthma can prevent major outcomes such as admission to hospital has yet to be studied.
METHODS—A case-control study nested within a cohort of 13 563 newly treated asthmatic subjects selected from the databases of Saskatchewan Health (1977-1993) was undertaken to investigate the effectiveness of a first treatment with inhaled corticosteroids in preventing admissions to hospital for asthma. Study subjects were aged between five and 44 years at cohort entry. First time users of inhaled corticosteroids were compared with first time users of theophylline for a maximum of 12 months of treatment. The two treatments under study were further classified into initial and subsequent therapy to minimise selection bias and confounding by indication. Odds ratios associated with hospital admissions for asthma were estimated using conditional logistic regression. Markers of asthma severity, as well as age and sex, were considered as potential confounders.
RESULTS—Three hundred and three patients admitted to hospital with asthma were identified and 2636 matched controls were selected. Subjects initially treated with regular inhaled corticosteroids were 40% less likely to be admitted to hospital for asthma than regular users of theophylline (odds ratio 0.6; 95% CI 0.4 to 1.0). The odds ratio decreased to 0.2 (95% CI 0.1 to 0.5) when inhaled corticosteroids and theophylline were given subsequently.
CONCLUSION—The first regular treatment with inhaled corticosteroids initiated in the year following the recognition of asthma can reduce the risk of admission to hospital for asthma by up to 80% compared with regular treatment with theophylline. This is probably due, at least in part, to reducing the likelihood of a worsening in the severity of asthma.



Full Text

The Full Text of this article is available as a PDF (109.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agertoft L., Pedersen S. Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. Respir Med. 1994 May;88(5):373–381. doi: 10.1016/0954-6111(94)90044-2. [DOI] [PubMed] [Google Scholar]
  2. Barnes P. J. Inhaled glucocorticoids for asthma. N Engl J Med. 1995 Mar 30;332(13):868–875. doi: 10.1056/NEJM199503303321307. [DOI] [PubMed] [Google Scholar]
  3. Crane J., Pearce N., Burgess C., Woodman K., Robson B., Beasley R. Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. Int J Epidemiol. 1992 Aug;21(4):737–744. doi: 10.1093/ije/21.4.737. [DOI] [PubMed] [Google Scholar]
  4. Ernst P., Spitzer W. O., Suissa S., Cockcroft D., Habbick B., Horwitz R. I., Boivin J. F., McNutt M., Buist A. S. Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA. 1992 Dec 23;268(24):3462–3464. [PubMed] [Google Scholar]
  5. Geddes D. M. Inhaled budesonide for mild asthma. N Engl J Med. 1995 Mar 9;332(10):683–684. doi: 10.1056/NEJM199503093321014. [DOI] [PubMed] [Google Scholar]
  6. Greenland S. Modeling and variable selection in epidemiologic analysis. Am J Public Health. 1989 Mar;79(3):340–349. doi: 10.2105/ajph.79.3.340. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Haahtela T., Järvinen M., Kava T., Kiviranta K., Koskinen S., Lehtonen K., Nikander K., Persson T., Reinikainen K., Selroos O. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med. 1991 Aug 8;325(6):388–392. doi: 10.1056/NEJM199108083250603. [DOI] [PubMed] [Google Scholar]
  8. Haahtela T., Järvinen M., Kava T., Kiviranta K., Koskinen S., Lehtonen K., Nikander K., Persson T., Selroos O., Sovijärvi A. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med. 1994 Sep 15;331(11):700–705. doi: 10.1056/NEJM199409153311103. [DOI] [PubMed] [Google Scholar]
  9. Israel E., Drazen J. M. Treating mild asthma--when are inhaled steroids indicated? N Engl J Med. 1994 Sep 15;331(11):737–739. doi: 10.1056/NEJM199409153311110. [DOI] [PubMed] [Google Scholar]
  10. Janson-Bjerklie S., Ferketich S., Benner P., Becker G. Clinical markers of asthma severity and risk: importance of subjective as well as objective factors. Heart Lung. 1992 May;21(3):265–272. [PubMed] [Google Scholar]
  11. Juniper E. F., Kline P. A., Vanzieleghem M. A., Ramsdale E. H., O'Byrne P. M., Hargreave F. E. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis. 1990 Oct;142(4):832–836. doi: 10.1164/ajrccm/142.4.832. [DOI] [PubMed] [Google Scholar]
  12. Krahn M. D., Berka C., Langlois P., Detsky A. S. Direct and indirect costs of asthma in Canada, 1990. CMAJ. 1996 Mar 15;154(6):821–831. [PMC free article] [PubMed] [Google Scholar]
  13. König P. Inhaled budesonide for mild asthma. N Engl J Med. 1995 Mar 9;332(10):683–684. [PubMed] [Google Scholar]
  14. Laitinen L. A., Laitinen A., Haahtela T. A comparative study of the effects of an inhaled corticosteroid, budesonide, and a beta 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J Allergy Clin Immunol. 1992 Jul;90(1):32–42. doi: 10.1016/s0091-6749(06)80008-4. [DOI] [PubMed] [Google Scholar]
  15. Laitinen L. A., Laitinen A., Haahtela T. Airway mucosal inflammation even in patients with newly diagnosed asthma. Am Rev Respir Dis. 1993 Mar;147(3):697–704. doi: 10.1164/ajrccm/147.3.697. [DOI] [PubMed] [Google Scholar]
  16. Lubin J. H., Gail M. H. Biased selection of controls for case-control analyses of cohort studies. Biometrics. 1984 Mar;40(1):63–75. [PubMed] [Google Scholar]
  17. Rea H. H., Scragg R., Jackson R., Beaglehole R., Fenwick J., Sutherland D. C. A case-control study of deaths from asthma. Thorax. 1986 Nov;41(11):833–839. doi: 10.1136/thx.41.11.833. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Selroos O., Pietinalho A., Löfroos A. B., Riska H. Effect of early vs late intervention with inhaled corticosteroids in asthma. Chest. 1995 Nov;108(5):1228–1234. doi: 10.1378/chest.108.5.1228. [DOI] [PubMed] [Google Scholar]
  19. Slone D., Shapiro S., Miettinen O. S., Finkle W. D., Stolley P. D. Drug evaluation after marketing. Ann Intern Med. 1979 Feb;90(2):257–261. doi: 10.7326/0003-4819-90-2-257. [DOI] [PubMed] [Google Scholar]
  20. Strom B. L., Melmon K. L. Can postmarketing surveillance help to effect optimal drug therapy? JAMA. 1979 Nov 30;242(22):2420–2422. [PubMed] [Google Scholar]
  21. Strom B. L., Melmon K. L., Miettinen O. S. Post-marketing studies of drug efficacy: why? Am J Med. 1985 Mar;78(3):475–480. doi: 10.1016/0002-9343(85)90341-9. [DOI] [PubMed] [Google Scholar]
  22. Strom B. L., Miettinen O. S., Melmon K. L. Post-marketing studies of drug efficacy: how? Am J Med. 1984 Oct;77(4):703–708. doi: 10.1016/0002-9343(84)90369-3. [DOI] [PubMed] [Google Scholar]
  23. Weiss K. B., Gergen P. J., Hodgson T. A. An economic evaluation of asthma in the United States. N Engl J Med. 1992 Mar 26;326(13):862–866. doi: 10.1056/NEJM199203263261304. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES